Advanced Filters
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
noise

Found 2,822 clinical trials

L Louis Grandjean, Dr

COVID-19 Staff Testing of Antibody Responses Study (Co-Stars)

This study will perform prospective repeated serological antibody testing on a cohort of at least 1000 healthcare workers at Great Ormond Street Hospital. Within this cohort, a subset of 150-250 staff members with confirmed (PCR positive) SARS-CoV-2 disease will be followed with intensive monthly testing for 6 months to determine …

18 years and older All Phase N/A
V Véronique Lelong-Boulouard, PhD, PharmD

Evaluation of Reporting of Road Traffic Accidents With Drugs Responsible for Cognitive Side Effects (ERoADS)

Drugs responsible for cognitive and psychomotor side effects may lead to impaired driving skills and road traffic accidents. This study investigates reports of road traffic accident for different class of drugs responsible for cognitive and psychomotor sides effects (pyschotropic agents, neurotropic agents, antineoplasic agents) in the World Health Organization's (WHO) …

18 years and older All Phase N/A
S Sarah B Burris, MHA

Early Onset Alzheimer's Disease Genomic Study

The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis. Samples will be studied in order to understand how molecular changes in the body are related to the development of the disease. Researchers will study your …

40-65 years All Phase N/A
Y Yanxia Guo, M.D.

Gut Microbiota and Alzheimer's Diseases

The investigator will perform clinical studies to test the hypothsis that participants who had Alzhemer's disease will have different gut microbiota in the feaces as compared to participants who did not have Alzhemer's disease, as well as compared to their spouse.The investigators plan to perfoem the studies in 150 participants …

60 years and older All Phase N/A
K Kristina Balderson

Blood Biomarker of Alzheimer's Disease (AD)

Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as …

50 years and older All Phase N/A
D Douglas Merkitch

Antigen Presentation and Lymphocyte Response in Parkinson's Disease

The way the immune system responds to certain PD-related proteins in PD donors compared to the way it responds in persons without or fewer PD related proteins is not well studied and this study aims to analyze the autoimmune response in each group. The study involves a one time visit …

50-90 years All Phase N/A
R REACH-PD Clinical Research Study Team

Deep Brain Stimulation (DBS) for Parkinson's Disease International Study

To gather data on DBS Therapy effectiveness in different geographic populations.

22 years and older All Phase N/A
C Carissa Walter, MPH

Accuracy of TCOM vs NIRS in Predicting Wound Outcomes in Patients Treated With or Without Revascularization

The primary purpose of this project is to compare the accuracy of transcutaneous oxygen monitoring and near infrared spectroscopy in assessing cutaneous oxygen levels in chronic wounds of patients following revascularization procedures as well as those with conservatively managed chronic wounds. This study will also compare the efficiency and practicality …

18-85 years All Phase N/A
U US Biogen Clinical Trial Center

Dimethyl Fumarate (DMF Tecfidera ) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP

The primary objective is to compare oral dimethyl fumarate (DMF) persistence at six months in relapsing-remitting multiple sclerosis (RR-MS) participants initiating DMF with and without OroSEP patient support program (PSP), respectively. The secondary objectives are: to compare oral DMF persistence at one month and three months in RR-MS participants initiating …

18-55 years All Phase N/A
C Crystee Cooper, DHEd

Pre-hospital Tourniquet in Extremity Injury

2.1. Objective: Primary Objective: To compare outcomes of patients with extremity injuries presenting with or without pre-hospital tourniquet placement. 2.2. Study Outcome Measures Primary Outcome: Incidence of arrival in shock (SBP <90) Secondary Outcomes: Demographics, comorbidities, mechanism of injury, cause of injury, diagnosis codes, procedure codes, ISS, AIS, operative management …

18 years and older All Phase N/A

Simplify language using AI